Novavax (NVAX) Other Non-Current Liabilities (2010 - 2026)
Novavax (NVAX) posted quarterly Other Non-Current Liabilities of $193.2 million for Q1 2026, down 38.4% year-over-year from $313.7 million in Q1 2025, and down 19.17% quarter-over-quarter from $239.1 million in Q4 2025.
Novavax (NVAX) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Novavax's Other Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $193.2 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 38.4% year-over-year to $193.2 million; the TTM figure through Mar 2026 stood at $193.2 million (down 38.4% YoY), while the FY2025 annual figure was $239.1 million, down 33.52% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $193.2 million, down from $239.1 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $359.6 million in Q4 2024, with the low at $33.1 million in Q4 2023.
- The 5-year median for Other Non-Current Liabilities is $193.2 million (2026), against an average of $182.9 million.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities slumped 62.16% in 2023, then jumped 985.46% in 2024.
- Novavax's Other Non-Current Liabilities stood at $55.7 million in 2022, then sank by 40.52% to $33.1 million in 2023, then surged by 985.46% to $359.6 million in 2024, then sank by 33.52% to $239.1 million in 2025, then fell by 19.17% to $193.2 million in 2026.
- Business Quant data shows NVAX's Other Non-Current Liabilities at $193.2 million in Q1 2026, $239.1 million in Q4 2025, and $263.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Novavax | 1.33 Bn | 607.37 Mn | 42.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 165.74 Mn |
| Mar 31, 2026 | 193.24 Mn |
| Dec 31, 2025 | 239.07 Mn |
| Sep 30, 2025 | 263.48 Mn |
| Jun 30, 2025 | 287.59 Mn |
| Mar 31, 2025 | 313.73 Mn |
| Dec 31, 2024 | 359.61 Mn |
| Sep 30, 2024 | 318.92 Mn |
| Jun 30, 2024 | 335.29 Mn |
| Mar 31, 2024 | 351.72 Mn |
| Dec 31, 2023 | 33.13 Mn |
| Sep 30, 2023 | 37.30 Mn |
| Jun 30, 2023 | 38.38 Mn |
| Mar 31, 2023 | 47.51 Mn |
| Dec 31, 2022 | 55.70 Mn |
| Sep 30, 2022 | 98.57 Mn |
| Jun 30, 2022 | 69.08 Mn |
| Mar 31, 2022 | 66.80 Mn |
| Dec 31, 2021 | 42.12 Mn |
| Sep 30, 2021 | 28.09 Mn |